What molecule am I?


Triruthenium dodecacarbonyl [Ru3(CO)12] is a coordination compound that consists of a triangle of ruthenium atoms, each of which is bonded to four carbon monoxide molecules. It appears as dark orange crystals that are soluble in nonpolar solvents but not in water.
Ru3(CO)12 and the similar osmium dodecacarbonyl1 [Os3(CO)12] were to have the formulas Ru2(CO)9 and Os2(CO)9, respectively. But an extensive analysis in 1961 by Eugene E. Corey and Lawrence F. Dahl* at the University of Wisconsin (Madison) revealed the of the molecules. The authors used crystallographic and spectroscopic evidence to establish the molecular structures.
Ru3(CO)12 is synthesized via the base-catalyzed liquid-phase reaction of ruthenium trichloride2 (RuCl3) with CO. It also has been made under high CO pressure from ruthenium stearate3 dissolved in cyclohexane or from RuCl3 and metallic zinc in ethanol.
The primary use for Ru3(CO)12 is the synthesis of other ruthenium complexes, many with CO combined with other ligands such as alkenes. Two recent patents to Tokyo Electron Ltd. (Tokyo) describe its use for making ruthenium films deposited on silicon substrates that form semiconductors.
This year, Ru3(CO)12 has also been used for an educational purpose. It, along with six other inorganic molecules with varying types of symmetry, were examples used by Donald J. Wink and collaborators at the University of Illinois Chicago to instruct students to . The activity included student-created 2-D drawings and 3-D molecular models.
Considering that CO and most ruthenium compounds are highly toxic, Ru3(CO)12 exhibits remarkably few hazards.
1. CAS Reg. No. 15696-40-9.
2. CAS Reg. No. 10049-08-8.
3. CAS Reg. No. 153728-81-5.
Triruthenium dodecacarbonyl hazard information
Hazard class* | GHS code and hazard statement | |
---|---|---|
Acute toxicity, inhalation, category 4 | H332鈥擧armful if inhaled | ![]() |
*Globally Harmonized System (GHS) of Classification and Labeling of Chemicals.聽.
Molecule of the Future
Ganaplacide1 is an antimalarial agent in the imidazolopiperazine family that is being developed by Novartis (Basel, Switzerland) with support from the Medicine for Malaria Venture (MMV), a multinational nonprofit organization. New drugs are needed because artemisinin2, artemether3, and other treatments are becoming resistant to malaria-causing parasites.

In 2012, Arnab K. Chatterjee at Novartis鈥檚 Genomics Institute (San Diego) and colleagues there and at Novartis facilities in Cambridge, MA, and Singapore; the Swiss Tropical and Public Health Institute (Basel); and the University of Basel reported the to replace current drugs. Ganaplacide was eventually chosen as the molecule for development; and in November 2022, Novartis and MMV announced that it, in combination with lumefantrine4 (a compound previously used with artemether), would transition to a for treating patients with acute uncomplicated malaria. The study was scheduled to begin this year.
1. CAS Reg. No. 1261113-96-5.
2. CAS Reg. No. 63968-64-9.
3. CAS Reg. No. 71963-77-4.
4. CAS Reg. No. 82186-77-4.
Molecule of the Future
Once a month we bring you a newly discovered or developed molecule that has important implications for the future of chemistry or society in general. Look for it the third week of each month.聽Learn more about this month's Molecule of the Future.
We're looking for more molecules of the future!
Do you have a suggestion for the next molecule of the future? Send your idea to MOTW.
This molecule was suggested by a reader. We present聽almost all of the molecules suggested by our readers.聽If you have a molecule you would like us to consider, please send us a message. And thank you for your interest in Molecule of the Week! 鈥擡d.
Triruthenium dodecacarbonyl聽Fast Facts
CAS Reg. No. | 15243-33-1 |
SciFinder nomenclature | Ruthenium, dodecacarbonyltri-, triangulo |
Empirical formula | C12O12Ru3 |
Molar mass | 639.33 g/mol |
Appearance | Orange crystals or powder |
Melting point | 150 掳C (dec.)a |
Water solubility | Insoluble |
a. Also reported as 224 掳C without decomposition.
MOTW update
Ellagic acid1 was the Molecule of the Week for January 23, 2003. It is a natural polyphenol that was originally used in tanning agents; but more recently, it has shown potential health benefits such as treating breast cancer and gut inflammation. This month, Ruili Yang and co-workers at South China Agricultural University (Guangzhou) reported that ellagic acid, by metabolizing to urolithin A2, by reducing cognitive impairment, increasing 纬-aminobutyric acid and serotonin levels, and suppressing inflammatory and oxidative stress.
1. CAS Reg. No. 476-66-4.
2. CAS Reg. No. 1143-70-0.

, the most authoritative and comprehensive source for chemical information.
Molecule of the Week needs your suggestions!
If your favorite molecule is not in our聽archive, please send us a message. The molecule can be notable for its current or historical importance or for any quirky reason. Thank you!
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.